Trial Profile
A Multicenter Open-Label Single-Arm Phase II Study Evaluating the Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Metastatic, Recurrent or Persistent Cervical Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Carcinoma; Cervical cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms CECILIA
- Sponsors Roche
- 04 Aug 2020 Final analysis (data cut off: December 31, 2018) published in the Gynecologic Oncology
- 01 Mar 2019 Status changed from active, no longer recruiting to completed.
- 22 Feb 2019 This trial was completed in France (end date-2018-12-31) according to European Clinical Trials Database record.